TY - JOUR
T1 - Platelet–Leucocyte Aggregates as Novel Biomarkers in Cardiovascular Diseases
AU - Pluta, Kinga
AU - Porębska, Kinga
AU - Urbanowicz, Tomasz
AU - Gąsecka, Aleksandra
AU - Olasińska-Wiśniewska, Anna
AU - Targoński, Radosław
AU - Krasińska, Aleksandra
AU - Filipiak, Krzysztof J.
AU - Jemielity, Marek
AU - Krasiński, Zbigniew
N1 - Publisher Copyright: © 2022 by the authors. Licensee MDPI, Basel, Switzerland.
PY - 2022/2/1
Y1 - 2022/2/1
N2 - Platelet–leucocyte aggregates (PLA) are a formation of leucocytes and platelets bound by specific receptors. They arise in the condition of sheer stress, thrombosis, immune reaction, vessel injury, and the activation of leukocytes or platelets. PLA participate in cardiovascular diseases (CVD). Increased levels of PLA were revealed in acute and chronic coronary syndromes, carotid stenosis cardiovascular risk factors. Due to accessible, available, replicable, quick, and low-cost quantifying using flow cytometry, PLA constitute an ideal biomarker for clinical practice. PLA are promising in early diagnosing and estimating prognosis in patients with acute or chronic coronary syndromes treated by percutaneous coronary intervention (PCI) and coronary artery bypass grafting (CABG). PLA were also a reliable marker of platelet activity for monitoring antiplatelet therapy. PLA consist also targets potential therapies in CVD. All of the above potential clinical applications require further studies to validate methods of assay and proof clinical benefits.
AB - Platelet–leucocyte aggregates (PLA) are a formation of leucocytes and platelets bound by specific receptors. They arise in the condition of sheer stress, thrombosis, immune reaction, vessel injury, and the activation of leukocytes or platelets. PLA participate in cardiovascular diseases (CVD). Increased levels of PLA were revealed in acute and chronic coronary syndromes, carotid stenosis cardiovascular risk factors. Due to accessible, available, replicable, quick, and low-cost quantifying using flow cytometry, PLA constitute an ideal biomarker for clinical practice. PLA are promising in early diagnosing and estimating prognosis in patients with acute or chronic coronary syndromes treated by percutaneous coronary intervention (PCI) and coronary artery bypass grafting (CABG). PLA were also a reliable marker of platelet activity for monitoring antiplatelet therapy. PLA consist also targets potential therapies in CVD. All of the above potential clinical applications require further studies to validate methods of assay and proof clinical benefits.
KW - Aggregates
KW - Biomarker
KW - Cardiovascular disease
KW - Flow cytometry
KW - Leucocyte
KW - Platelets
KW - Platelet–leucocyte aggregates
UR - http://www.scopus.com/inward/record.url?scp=85124020581&partnerID=8YFLogxK
U2 - https://doi.org/10.3390/biology11020224
DO - https://doi.org/10.3390/biology11020224
M3 - Review article
C2 - 35205091
SN - 2079-7737
VL - 11
JO - Biology
JF - Biology
IS - 2
M1 - 224
ER -